These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11496466)

  • 21. Pharmaceuticals in Australia: developments in regulation and governance.
    Lofgren H; Boer Rd
    Soc Sci Med; 2004 Jun; 58(12):2397-407. PubMed ID: 15081192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. A proposal for a new authority category.
    Glasziou PP
    Med J Aust; 1995 Jan; 162(1):33-6. PubMed ID: 7605432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Government commitment and regulation of prescription drugs.
    Frank RG
    Health Aff (Millwood); 2003; 22(3):46-8. PubMed ID: 12757271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Support for trials of promising medications through the Pharmaceutical Benefits Scheme.
    Bell KD
    Med J Aust; 1995 Apr; 162(8):447; author reply 447-8. PubMed ID: 7746194
    [No Abstract]   [Full Text] [Related]  

  • 25. The need for health care reform.
    Mossinghoff GJ
    Health Syst Rev; 1994; 27(3):5-6. PubMed ID: 10134516
    [No Abstract]   [Full Text] [Related]  

  • 26. A role for two-stage pharmacoeconomic appraisal? Is there a role for interim approval of a drug for reimbursement based on modelling studies with subsequent full approval using phase III data?
    Hill S; Freemantle N
    Pharmacoeconomics; 2003; 21(11):761-7. PubMed ID: 12859218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cost-effectiveness approach to drug subsidy and pricing in Australia.
    Birkett DJ; Mitchell AS; McManus P
    Health Aff (Millwood); 2001; 20(3):104-14. PubMed ID: 11585158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic evaluation for pharmaceuticals in Germany.
    Jönsson B
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
    [No Abstract]   [Full Text] [Related]  

  • 29. Why the Watchdog Won't Bite: U.S. Food and Drug Administration Challenges.
    Lex J
    West J Emerg Med; 2016 Nov; 17(6):747-748. PubMed ID: 27833683
    [No Abstract]   [Full Text] [Related]  

  • 30. Medicare Part D--the product of a broken process.
    Slaughter LM
    N Engl J Med; 2006 Jun; 354(22):2314-5. PubMed ID: 16738267
    [No Abstract]   [Full Text] [Related]  

  • 31. A perspective on Australia's National Medicines Policy.
    Tett SE
    Can J Clin Pharmacol; 2004; 11(1):e28-38. PubMed ID: 15226524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guidelines for measuring the costs and consequences of adopting new pharmaceutical products: are they on track?
    Pausjenssen AM; Detsky AS
    Med Decis Making; 1998; 18(2 Suppl):S19-22. PubMed ID: 9566463
    [No Abstract]   [Full Text] [Related]  

  • 33. Interorganizational networks for the care of the elderly in The Netherlands: possibilities and limitations.
    Mur-Veeman IM; vanRaak AJ
    Home Health Care Serv Q; 1995; 15(2):41-58. PubMed ID: 10143896
    [No Abstract]   [Full Text] [Related]  

  • 34. Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status?
    Drummond M
    Health Econ; 1992 Jul; 1(2):85-92. PubMed ID: 1341931
    [No Abstract]   [Full Text] [Related]  

  • 35. Riding high on a drug bill.
    Harrington A
    Fortune; 2003 Sep; 148(4):168. PubMed ID: 12964298
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmaceuticals and medical devices: business practices. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448
    [No Abstract]   [Full Text] [Related]  

  • 37. Regulating manufacturer-affiliated communication in the information age.
    Schulman KA; Abernethy DR; Rathore SS; Woosley RL
    Clin Pharmacol Ther; 1999 Jun; 65(6):593-7. PubMed ID: 10391664
    [No Abstract]   [Full Text] [Related]  

  • 38. PBMs: ripe for regulation.
    Johnson RS
    Food Drug Law J; 2002; 57(2):323-69. PubMed ID: 12437004
    [No Abstract]   [Full Text] [Related]  

  • 39. FDA dependence on drug industry.
    Lawson GW
    J Natl Med Assoc; 2005 Jul; 97(7):1039-40. PubMed ID: 16080677
    [No Abstract]   [Full Text] [Related]  

  • 40. Oncology pharmaceutical funding in New Zealand: a different approach and a proposal.
    Beatty PA; Laking GR
    J Oncol Pract; 2015 May; 11(3):249-51. PubMed ID: 25829524
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.